Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07509424 Sintilimab Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509424 clinical trial report covering Sintilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07510334 Ipilimumab Metastatic Clear Cell Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07510334 clinical trial report covering Ipilimumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07509515 QLC5513 Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509515 clinical trial report covering QLC5513, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07510594 Anlotinib Dihydrochloride Large cell neuroendocrine carcinoma of lung Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07510594 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07509892 TQH-3906 Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509892 clinical trial report covering TQH-3906, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07509112 Semaglutide (Novo Nordisk) Methamphetamine abuse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509112 clinical trial report covering Semaglutide (Novo Nordisk), Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07512700 Venetoclax Acute Monocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07512700 clinical trial report covering Venetoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07508995 Sonrotoclax Chronic Lymphocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07508995 clinical trial report covering Sonrotoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07511972 Pembrolizumab Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07511972 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07511725 Thiotepa Glioblastoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07511725 clinical trial report covering Thiotepa, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07512674 Bevacizumab pMMR/MSS/MSI-L Colon Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07512674 clinical trial report covering Bevacizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07511504 Tremelimumab Locally Advanced Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07511504 clinical trial report covering Tremelimumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.